FOEHR MATTHEW W 4

4 · Viking Therapeutics, Inc. · Filed Jan 5, 2026

Form 4

Period: 2026-01-02

Director

Transactions

Exercise/Conversion
Common Stock, par value $0.00001 per share
2026-01-02$3.33/sh+16,000$53,280→ 148,036 total
Sale
Common Stock, par value $0.00001 per share
2026-01-02$35.11/sh−16,000$561,694→ 132,036 total
Award
Common Stock, par value $0.00001 per share
2026-01-02+3,150→ 135,186 total
Exercise/Conversion
Stock Option (Right to Buy)
2026-01-02−16,000→ 0 total
Exercise: $3.33From: 2017-01-04Exp: 2026-01-04→ Common Stock (16,000 underlying)
Award
Stock Option (Right to Buy)
2026-01-02+20,400→ 20,400 total
Exercise: $35.42From: 2027-01-02Exp: 2036-01-02→ Common Stock (20,400 underlying)

Footnotes (2)

[F1]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
[F2]Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.

Documents

1 file